Address & contact
https://investor.igcpharma.com/igc-pharma-secures-psilocybin-research-authorization-expanding-focus-on-neuropsychiatric-symptoms-in-dementia/Specialties
Reports that name this provider
- Psilocybin Treatment Legality in Colombia
- April 2026 authorization from Fondo Nacional de Estupefacientes (FNE) to synthesize and formulate psilocybin at a research facility for preclinical dementia research; described as one of a limited number of organizations in Colombia with this type of authorization
- Psychedelic Treatment Quality in Colombia
- April 2026 authorization from Fondo Nacional de Estupefacientes (FNE) to synthesize and formulate psilocybin at Bogotá R&D facility for research purposes (not clinical treatment)